Long‐Term Efficacy and Safety of Glycerol Phenylbutyrate in Japanese Patients With Urea Cycle Disorders: Results From a Phase 3 Switch‐Over and 12‐Month Extension Study
JIMD Reports · 2026-07 · 67 (4)
DOI: 10.1002/jmd2.70082 ↗Kurz gefasst
Fachartikel in der Zeitschrift JIMD Reports, online erschienen am 14.06.2026. Verfasst von Yoichi Wada und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Science and Innovation SiRIUS Institute of Medical Research Sendai Japan. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Sodium phenylbutyrate (NaPBA) is used for nitrogen scavenging in urea cycle disorders (UCDs), but its volume, palatability, and sodium load affect adherence and ammonia control. Glycerol phenylbutyrate (GPB) offers an alternative option with demonstrated improvements in metabolic control and palatability. For a Japanese perspective, we undertook an open‐label, multicentre, prospective Phase 3 study of efficacy, pharmacokinetics (PK), and safety. In a switch‐over, 15 patients received NaPBA for 7 days, then GPB for 7 days. Primary endpoint: 24‐h blood ammonia AUC (AUC NH3,0–24 ). Secondary endpoints: blood ammonia and glutamine concentration; PK of scavenger metabolites in blood and urine; safety. Patients then received GPB for up to 12 months. For GPB and NaPBA, respectively, mean (SD) AUC NH3,0–24 was 627 (198) and 757 (307) μmol·h/L (ratio 0.849; 95% CI 0.723–0.997). Mean peak and mean blood ammonia were 37 and 26 μmol/L versus 52 and 32 μmol/L. Mean plasma AUC 0–24 for phenylbutyrate (PBA), phenylacetate (PAA), and phenylacetylglutamine (PAGN) were 470, 1420, and 836 versus 425, 984, and 741 μg·h/mL. Mean PBA metabolite fluctuation was 297% versus 366%. One adverse event (hyperammonaemia) led to discontinuation in each treatment arm. In the extension ( n = 14), mean (SD) blood ammonia at Month 12 was 21 (8) μmol/L. No new safety findings were observed. GPB demonstrated effective control of blood ammonia with a favourable safety profile. It offers a practical and clinically advantageous alternative to NaPBA, extending previous evidence to Japanese individuals with UCDs. Trial registration: jRCT2071220110.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical Science and Innovation SiRIUS Institute of Medical Research Sendai Japan.
- Department of Pediatrics Tohoku University Hospital Sendai Japan.
- Department of Pediatrics Okayama Medical Center Okayama Japan.
- Division of Endocrinology and Metabolism National Center for Child Health and Development Tokyo Japan.
- Department of Pediatrics Osaka Metropolitan University Osaka Japan.
- Department of Pediatrics Niigata University Medical and Dental Hospital Niigata Japan.
ORCID-Profile: Yoichi Wada, Kenichi Kashimada, Hiromi Nyuzuki, Keiko Ichimoto, Toshihiko Kakiuchi
Zitieren
APA
Wada, Y., Furujo, M., Kashimada, K., Hamazaki, T., Nyuzuki, H., Ichimoto, K., Kakiuchi, T., Matsumoto, S., Watanabe, Y., Ono, C., Shimizu, T., Furukawa, H., & Nakamura, K. (2026). Long‐Term Efficacy and Safety of Glycerol Phenylbutyrate in Japanese Patients With Urea Cycle Disorders: Results From a Phase 3 Switch‐Over and 12‐Month Extension Study. JIMD Reports, 67(4). https://doi.org/10.1002/jmd2.70082
Vancouver
Wada Y, Furujo M, Kashimada K, Hamazaki T, Nyuzuki H, Ichimoto K, et al. Long‐Term Efficacy and Safety of Glycerol Phenylbutyrate in Japanese Patients With Urea Cycle Disorders: Results From a Phase 3 Switch‐Over and 12‐Month Extension Study. JIMD Reports. 2026;67(4). doi:10.1002/jmd2.70082
BibTeX
@article{Wada2026,
author = {Wada, Yoichi and Furujo, Mahoko and Kashimada, Kenichi and Hamazaki, Takashi and Nyuzuki, Hiromi and Ichimoto, Keiko and Kakiuchi, Toshihiko and Matsumoto, Shirou and Watanabe, Yoriko and Ono, Chiho and Shimizu, Takako and Furukawa, Hiroiku and Nakamura, Kimitoshi},
title = {Long‐Term Efficacy and Safety of Glycerol Phenylbutyrate in Japanese Patients With Urea Cycle Disorders: Results From a Phase 3 Switch‐Over and 12‐Month Extension Study},
journal = {JIMD Reports},
year = {2026},
volume = {67},
number = {4},
doi = {10.1002/jmd2.70082}
}
EUVIMED